ALEC•benzinga•
Alector Highlights Strategic Focus For 2025, Phase 3 INFRONT-3 Data On Latozinemab For FTD-GRN By Q4 2025; 75% Enrollment For AL101 Trial In Early Alzheimer's Achieved; $457.2M Cash Expected To Fund Operations Through 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga